- Chairman of C4X Discovery, Non-Executive Director, Targovax and Crescendo Biologics (current)
- Previous Chief Business Officer at Immunocore and Chief Business Officer and member of the Executive Committee and Euronext IPO team at Ablynx NV
- Held senior positions at various large-cap biotechnology companies including Vertex Pharmaceuticals
Eva-Lotta Allan has more than 30 years of experience in the healthcare industry. During this time, she has been a senior executive and Board member at both public and private companies. Most recently, Eva-Lotta was Chief Business Officer (and previously a Board Member) at Immunocore, where she held full responsibility for all aspects of business development and played an instrumental role in the $320 million fundraising in 2015. Prior to this, Eva-Lotta served as Chief Business Officer and member of the Executive Committee and Euronext IPO team for Ablynx NV, acquired in 2018 by Sanofi for EUR 3.9 billion.
Eva-Lotta also held senior positions at Vertex Pharmaceuticals (Europe) Ltd, Oxford Asymmetry International plc (now Evotec), Oxford Glycosciences (now part of UCB Celltech) and Amersham International (now part of GE Healthcare).
Eva-Lotta Allan currently serves as Non-Executive Director and Member of the Corporate Governance Committee and the R&D Sub-Committee of the Oslo listed company, Targovax ASA and is a Non-Executive Director of Crescendo Biologics and Chairman of AIM-listed C4X Discovery. Eva-Lotta was also a Board Member of the UK BioIndustry Association (BIA).